Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 7/20 | 0.72 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.72 |
| ▸ | CYP1A1 | P04798 | 4/20 | 0.72 |
| ▸ | CYP1B1 | Q16678 | 4/20 | 0.72 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.72 |
| ▸ | MEN1 | O00255 | 3/20 | 0.72 |
| ▸ | MAPT | P10636 | 3/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.72 |
| ▸ | LMNA | P02545 | 3/20 | 0.72 |
| ▸ | TTR | P02766 | 3/20 | 0.72 |
| ▸ | CA12 | O43570 | 2/20 | 0.72 |
| ▸ | CA1 | P00915 | 2/20 | 0.72 |
| ▸ | CA2 | P00918 | 2/20 | 0.72 |
| ▸ | CA3 | P07451 | 2/20 | 0.72 |
| ▸ | CA4 | P22748 | 2/20 | 0.72 |
| ▸ | CA6 | P23280 | 2/20 | 0.72 |
| ▸ | CA5A | P35218 | 2/20 | 0.72 |
| ▸ | CA7 | P43166 | 2/20 | 0.72 |
| ▸ | CA9 | Q16790 | 2/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17570320 | 1.00 | PTGS1 (0.72) | PTGS1PTGS2KDM4ECYP1A1CYP1B1 | |
| SCHEMBL10281605 | 0.92 | PTGS1 (0.62) | PTGS1PTGS2KDM4ECYP1A1CYP1B1 | |
| SCHEMBL716460 | 0.91 | APP (0.64) | PTGS1PTGS2KDM4ECYP1A1CYP1B1 | |
| SCHEMBL716459 | 0.91 | APP (0.64) | PTGS1PTGS2KDM4ECYP1A1CYP1B1 | |
| SCHEMBL13409624 | 0.88 | APP (0.79) | PTGS1PTGS2KDM4ECYP1A1CYP1B1 | |
| SCHEMBL10184123 | 0.86 | KDM4E (0.62) | PTGS1PTGS2KDM4ECYP1A1CYP1B1 | |
| SCHEMBL12307322 | 0.85 | PTGS2 (0.79) | PTGS1PTGS2KDM4ECYP1A1CYP1B1 | |
| Resveratrol SCHEMBL20603098 | 0.85 | KDM4E (0.91) | PTGS1PTGS2KDM4ECYP1A1CYP1B1 | |
| Resveratrol SCHEMBL20603099 | 0.85 | KDM4E (0.91) | PTGS1PTGS2KDM4ECYP1A1CYP1B1 | |
| Resveratrol SCHEMBL19426 | 0.84 | PTGS1 (1.00) | PTGS1PTGS2KDM4ECYP1A1CYP1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12029706-B2 | Methods for treating mucopolysaccharidosis | UNIVERSITY OF MIAMI (US) | 2024-07-09 | — | — | US | disclosed |
| WO-2023110270-A1 | POLYTHIOL COMPOUNDS AND PROCESS FOR PREPARATION THEREOF | HENKEL AG & CO. KGAA (DE) | 2023-06-22 | — | — | WO | disclosed |
| EP-4198018-A1 | POLYTHIOL COMPOUNDS AND PROCESS FOR PREPARATION THEREOF | Henkel AG & Co. KGaA (DE) | 2023-06-21 | — | — | EP | disclosed |
| EP-3134421-B1 | NEW LIPOPHENOL COMPOUNDS AND USES THEREOF | INST NAT SANTE RECH MED (FR) | 2022-04-20 | — | — | EP | disclosed |
| EP-3654984-B1 | TOPICAL TREATMENT FOR PREVENTING AND MITIGATING SKIN CYTOTOXICITY DUE TO THERAPY WITH TYROSINE KINASE INHIBITORS | EUCARE S R L (IT) | 2021-06-16 | — | — | EP | disclosed |
| US-20190218181-A1 | PROCESS FOR THE MANUFACTURE OF HYDROXY-SUBSTITUTED AROMATIC COMPOUNDS | BASF PERSONAL CARE AND NUTRITION GMBH (DE) | 2019-07-18 | — | — | US | disclosed |
| US-20180221514-A1 | NITROXIDE CONTAINING AMYLOID BINDING AGENTS FOR IMAGING AND THERAPEUTIC USES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2018-08-09 | — | — | US | disclosed |
| WO-2018087305-A1 | FUNCTIONAL CHOCOLATE | IMMD SP. Z O.O. (PL) | 2018-05-17 | — | — | WO | disclosed |
| US-9925153-B2 | Therapeutic agents for skin diseases and conditions | STC.UNM (US) | 2018-03-27 | — | — | US | disclosed |
| US-20170319611-A1 | METHODS AND COMPOSITIONS COMPRISING AKT INHIBITORS AND/OR PHOSPHOLIPASE D INHIBITORS | UNIV VANDERBILT (US) | 2017-11-09 | — | — | US | disclosed |
| EP-2514426-A1 | COMPOUNDS HAVING ANTI-INFLAMMATORY ACTIVITY | Consejo Superior De Investigaciones Científicas (CSIC) (ES) | 2012-10-24 | — | — | EP | disclosed |
| EP-1856251-B1 | METABOLICALLY ENGINEERED CELLS FOR THE PRODUCTION OF RESVERATROL OR AN OLIGOMERIC OR GLYCOSIDICALLY-BOUND DERIVATIVE THEREOF | FLUXOME SCIENCES AS (DK) | 2012-10-10 | — | — | EP | disclosed |
| US-20120135091-A1 | METHODS AND COMPOSITIONS FOR ENHANCING LIFESPAN INVOLVING SIRTUIN-MODULATING COMPOUNDS AND CHALCOGENIDES | US ARMY, SECRETARY OF THE ARMY | 2012-05-31 | — | — | US | disclosed |
| US-8017634-B2 | Compositions for treating obesity and insulin resistance disorders | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2011-09-13 | — | — | US | disclosed |
| WO-2010106082-A1 | ANTI-INFLAMMATORY AND ANTIOXIDANT CONJUGATES USEFUL FOR TREATING METABOLIC DISORDERS | GENMEDICA THERAPEUTICS SL (ES) | 2010-09-23 | — | — | WO | disclosed |
| US-7544497-B2 | Compositions for manipulating the lifespan and stress response of cells and organisms | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2009-06-09 | — | — | US | disclosed |
| EP-2060255-A2 | Methods and compositions for prevention and treatment of inflammatory disease, autoimmune disease, and transplant rejection | The Regents Of The University Of California (US) | 2009-05-20 | — | — | EP | disclosed |
| US-7384920-B2 | Use of stilbene compounds in the manufacture of medicament for the prevention and treatment of diabetes or retrovirus-associated diseases | INSTITUTE OF RADIATION MEDICINE, ACADEMY OF MILITARY MEDICAL SCIENCES, PLA (CN) | 2008-06-10 | — | — | US | disclosed |
| US-20070037739-A1 | Compounds useful in coating stents to prevent and treat stenosis and restenosis | MEDLOGICS DEVICE CORPORATION (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070014833-A1 | Treatment of eye disorders with sirtuin modulators | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12029706-B2 | Methods for treating mucopolysaccharidosis | GAA, MAN2B1, IDUA | PTGS1 3125/4885PTGS2 3036/4885KDM4E 3519/4885 |
| US-20180221514-A1 | NITROXIDE CONTAINING AMYLOID BINDING AGENTS FOR IMAGING AND THERAPEUTIC USES | APP, APBA1, CRYAB | PTGS1 1331/4885PTGS2 1327/4885KDM4E 3581/4885 |
| US-20070014833-A1 | Treatment of eye disorders with sirtuin modulators | SIRT1, SIRT2, SIRT3 | PTGS1 1853/4885PTGS2 2158/4885KDM4E 434/4885 |
| US-20120135091-A1 | METHODS AND COMPOSITIONS FOR ENHANCING LIFESPAN INVOLVING SIRTUIN-MODULATING COMPOUNDS AND CHALCOGENIDES | HSF1, SIRT1, SIRT2 | PTGS1 168/4885PTGS2 192/4885KDM4E 1777/4885 |
| US-20170319611-A1 | METHODS AND COMPOSITIONS COMPRISING AKT INHIBITORS AND/OR PHOSPHOLIPASE D INHIBITORS | PLD1, PLD2, PIK3CD | PTGS1 1613/4885PTGS2 2098/4885KDM4E 3540/4885 |
| US-20190218181-A1 | PROCESS FOR THE MANUFACTURE OF HYDROXY-SUBSTITUTED AROMATIC COMPOUNDS | HPD, HAAO, PAH | PTGS1 1636/4885PTGS2 2088/4885KDM4E 302/4885 |
| US-20070037739-A1 | Compounds useful in coating stents to prevent and treat stenosis and restenosis | CAD, DBNL, DCAF15 | PTGS1 2813/4885PTGS2 3835/4885KDM4E 4121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.